Close menu




January 12th, 2022 | 12:54 CET

Tilray, Ayurcann, Aurora Cannabis - When will the boom 2.0 come?

  • Cannabis
Photo credits: pixabay.com

About five years ago, the boom of cannabis stocks started. Companies like Aurora Cannabis, Canopy Growth and Tilray were able to multiply within a few months. However, the boom was followed by a quick end on the stock market. With corrections of 90% in some cases, the exaggerations were harshly corrected. However, the cannabis market is still in a strong growth phase. The legalization in many countries and the cannabis 3.0 wave promise the companies enormous growth leaps in the next few years. Thus, the steep rise seen at the time could be repeated, at least to some extent.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: TILRAY INC. CL.2 DL-_0001 | US88688T1007 , AYURCANN HOLDINGS CORP | CA05476A1012 , AURORA CANNABIS | CA05156X8843

Table of contents:


    Change of favorites in the cannabis industry

    While the stars of the industry half a decade ago were the aforementioned Tilray, Aurora and Canopy Growth, new companies such as Ayurcann, founded in 2018 and based in Pickering, Canada, are now pulling ahead. Unlike its peer group, its revenues grow quarter over quarter with positive operating income and consistent profitability. For the three months ended September 30, 2021, the Canadians reported net sales of CAD 1.9 million, up from CAD 0.8 million for the three months ended September 30, 2020, a 137% increase on the same quarter the previous year.

    Those looking for new cannabis products will come across Ayurcann's exclusive partnerships with national and international brands, including the UK-based Xplor. It offers highly potent active components in both THC and CBC at an exceptional value, making it unique in the market. Other international customers using Ayurcann's current product portfolio of over 40 products include Green Bee, Her Highness from the USA and Innocan Pharma from Israel. Recently, the market launch of the THC vape with high active ingredient content of the brand "Fuego" was announced.

    High demand leads to capacity expansion

    Ayurcann is white labeling and taking on the role of one of the leading B2B post-harvest solution providers to deliver scalable custom processes and pharma-grade products to Canada's recreational and medical cannabis industries. To meet increasing demand, the Phase 2 expansion of the Pickering facility was completed, increasing extraction capacity to up to 300,000 kg of input biomass and 2 to 3 million cannabis 2.0 and 3.0 products filled and packaged.

    Another distribution channel the Canadians have embarked on is the Ayurcann Marketplace. Qualified Canadian patients can easily access various products there while receiving privacy, security, support staff and medical professionals to help educate and prescribe cannabis to meet patient needs.

    The experienced management has a lot to live up to in this market. Yet the Company's stock market value, which is also traded in Frankfurt, is a manageable EUR 14.36 million.

    Convincing figures

    In contrast to the up-and-coming Ayurcann, Tilray, based in Nanaimo, British Columbia, has already established itself as a global player with a market capitalization of around 475 million. Tilray is one of the leading companies in the field of medical cannabis production and research. In the process, Tilray is one of the first GMP-certified manufacturers to export medical cannabis to 18 countries on 5 continents.

    The Canadians were able to deliver an encouraging set of results with the release of their fiscal 2022 second-quarter numbers. In the process, revenues were USD 155.15 million, up from USD 129.46 million in the same period last year. The results were below analysts' estimates, who had expected USD 170 million. However, earnings per share were better than expected with a black zero. The majority of analysts expected a loss of USD 0.084.

    The reaction to the strong figures was an increase of the share by more than 15% to USD 7.90. However, this level could not be held, so the support area at USD 6.88 is likely to be tested again. In general, the big players like Aurora Cannabis and Canopy Growth are still stuck in the correction cycle despite the horrendous losses.


    Although cannabis stocks remain in correction, the market is growing at double-digit rates, especially in Canada. Ayurcann stands out for its white label strategy of high growth while maintaining profitability. Lower prices are not unlikely for Aurora Cannabis and Tilray.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET

    Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Cannabis
    • Cancer

    Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.

    Read

    Commented by Armin Schulz on February 8th, 2023 | 11:49 CET

    BioNTech, Pfizer, Cardiol Therapeutics, Bayer - Biotech stocks facing a revival?

    • Biotechnology
    • Cancer
    • vaccine
    • Cannabis

    The BIO Deutschland association represents the German biotech industry. According to an announcement on January 18, financing of biotech companies plummeted by 2/3 in 2022. Overall, the sector raised only EUR 920 million in equity. During the Corona pandemic, many biotech stocks did well. Subsequently, profit-taking occurred and rising interest rates put additional pressure on stocks. That could change in 2023. Meanwhile, some companies are valued low, and so these companies appear on the radar of investors from the United States. According to Handelsblatt, Water Street, an investment company focused on pharma and biotech, has already invested EUR 1 billion, mainly in Germany. A total of EUR 6 billion is to be invested.

    Read

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read